Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and Mortality

Andrew Chiou, Bryant R. England, Harlan Sayles, Geoffrey M. Thiele, Michael J. Duryee, Joshua F. Baker, Namrata Singh, Grant W. Cannon, Gail S. Kerr, Andreas Reimold, Angelo Gaffo, Ted R. Mikuls

Research output: Contribution to journalArticle

Abstract

Objective: Although hyperuricemia and gout can complicate the course of rheumatoid arthritis (RA), the impact of these factors on outcomes in RA is unclear. We undertook this study to examine associations of coexistent hyperuricemia and gout with RA disease measures, RA treatments, and survival. Methods: Participants from a longitudinal RA study were categorized by the presence of gout and serum urate (UA) status. Groups were compared by baseline patient characteristics, RA disease activity, treatments, and comorbidities. Associations of baseline serum UA levels with all-cause and cardiovascular disease (CVD)–related mortality were examined in multivariable survival analyses. Results: Of 1,999 participants with RA, 341 (17%) had serum UA concentrations of >6.8 mg/dl, and 121 (6.1%) were diagnosed with gout. There were no significant associations of serum UA concentration or gout with RA disease activity or treatment at enrollment, with the exception that those with gout were more likely to be receiving sulfasalazine and less likely to be receiving nonsteroidal antiinflammatory drugs. After adjustments for age and sex, moderate hyperuricemia (serum UA >6.8 to ≤8 mg/dl) was associated with an increased risk of CVD-related mortality (hazard ratio 1.56 [95% confidence interval 1.11–2.21]). This association was attenuated and not significant following additional adjustment for comorbidities that more commonly accompany hyperuricemia. Results corresponding with serum UA concentrations of >8.0 mg/dl were similar, although not reaching statistical significance in any model. There were no associations of baseline serum UA concentration with all-cause mortality. Conclusion: Our study reports the frequency of hyperuricemia and gout in patients with RA. These results demonstrate strong associations of hyperuricemia with CVD mortality in this population, a risk that appears to be driven by excess comorbidity.

Original languageEnglish (US)
Pages (from-to)950-958
Number of pages9
JournalArthritis Care and Research
Volume72
Issue number7
DOIs
StatePublished - Jul 1 2020
Externally publishedYes

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and Mortality'. Together they form a unique fingerprint.

  • Cite this

    Chiou, A., England, B. R., Sayles, H., Thiele, G. M., Duryee, M. J., Baker, J. F., Singh, N., Cannon, G. W., Kerr, G. S., Reimold, A., Gaffo, A., & Mikuls, T. R. (2020). Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and Mortality. Arthritis Care and Research, 72(7), 950-958. https://doi.org/10.1002/acr.23926